Aqara Upgrades Iconic Cube Controller, Adding HomeKit and Alexa Support
23.11.2022 11:00:00 EET | Business Wire | Press release
Aqara, a leading provider of smart home products, introduces its new Cube T1 Pro, which is the updated version of its iconic wireless Cube controller. Built upon the success of its predecessor, the new cube adds HomeKit and Alexa support1, so that it can be used to control a wide range of smart home devices within both ecosystems. Moreover, it adds the new Scene Mode to allow users to use not only actions but also different sides of the cube to activate smart home scenes or devices2. The Cube T1 Pro is now available on Aqara Amazon brand stores in North America (US, Canada) and Europe (France, Germany, Italy, Spain, UK), and via selective Aqara retailers worldwide.
Similar to its predecessor, the Cube T1 Pro recognizes different actions such as push, shake, rotate, flip and tap. A new Scene Mode is added, and when the mode is activated the cube also recognizes different sides, so that users can simply use each side to control various scenes and devices. Dice-like indicators are printed on the sides to help users distinguish one from the others. Moreover, thanks to this new mode the Cube T1 Pro can be used in both HomeKit and Alexa. It’s also expected to support Matter via the Aqara hubs through an OTA update, and the Hub M2 will be the first hub to receive such update.
With all these improvements, the Cube T1 Pro enables a more intuitive way to control a smart home2. For instance, users can activate the Morning Routine by flipping it to Side 1, and trigger the Home Cinema Scene by flipping it to Side 2. Additionally, it’s now possible within the Aqara Home app to control more than one sets of curtains, roller shades or lights by rotating the new cube. For example, flipping it to Side 3 and rotating the cube to adjust the open percentage of the curtains, and flipping it to Side 4 and rotating to dim the Aqara lights3. The versatility of this cube controller allows users to be creative with their smart home setups.
Based on the Zigbee 3.0 protocol which allows faster response, higher reliability, better compatibility and improved energy efficiency, the Cube T1 Pro has a battery life of up to 2 years. It also supports OTA updates, which means that new features and fixes can be added to the new cube after the its initial release.
In celebration of the launch, Aqara now offers a 10% discount for the new cube on its Amazon stores. North American customers will enjoy the offer with the promo code NACUBET1 in the US and Canada, while European customers will enjoy it using the promo code CBT1PROEU in France, Germany, Italy, Spain and the UK. Both codes can be combined with coupon, and will be valid through November 24, 2022.
For more details of the Cube T1 Pro, please visit our website.
- A Zigbee 3.0-based Aqara hub is required. The Cube T1 Pro is recognized as 6 wireless buttons in HomeKit, and as 6 motion sensors in Alexa.
- A Zigbee 3.0-based Aqara hub is required.
- The compatible Aqara lights, Curtain Driver E1 or Roller Shade Driver E1 are required.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221123005015/en/
Contact information
For Media Inquiry:
media@aqara.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Netceed Strengthens Board with Global Infrastructure and Technology Leaders1.4.2026 15:00:00 EEST | Press release
Netceed, a global leader in delivering supply chain solutions across broadband, data center and energy infrastructure, today announced the appointment of Franck Bruel, Jan Frykhammar and Stacey Thompson to advise as strategic advisors to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401045867/en/ Franck Bruel Following the recently announced recapitalization of the Netceed Group and under the chairmanship of Rajeev Suri, the company is strengthening its Board with globally recognized leaders across telecommunications infrastructure, industrial distribution, energy infrastructure and hyperscale technology. Collectively, the new appointees bring decades of leadership experience across some of the world’s most influential infrastructure and technology companies, reflecting Netceed’s ambition to play a leading role in the next generation of global digital, AI and energy infrastructure. Rajeev Suri, Ch
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom